New Gene Target Could Improve Cholesterol Without Harming the Liver

Preclinical study identifies possible therapeutic target for cardiovascular risk factors that avoid the common problem of an increased risk of fatty liver disease.

9:38 AM

Author | Haley Otman

image of drawing of gene in blue ink on lined paper with lab note written on bottom right
Image by Stephanie King.

Medications to improve cholesterol and reduce cardiovascular risk factors can also put some patients at a higher risk for fatty liver disease or liver damage.

A new study from an international team of researchers points to a few genes as possible future targets to address cardiovascular risk without affecting the liver or causing other metabolic disorders.

"We know that some genes/proteins cause your cholesterol to either clog up your arteries or clog up your liver. We wanted to find genes that help people avoid it all: heart disease, diabetes and liver disease," explains co-corresponding author Cristen Willer, Ph.D., an associate professor of internal medicine, human genetics and computational medicine and bioinformatics, from the Michigan Medicine Frankel Cardiovascular Center.

Willer and colleagues identified 76 notable variants with potential, 11 of which were previously unreported. She says one in particular, known as ZNF529, was particularly interesting. People missing one copy of that gene had lower LDL cholesterol measures.

When the researchers in Y. Eugene Chen's Frankel CVC lab examined the gene in human liver cells, it had the same effect as a popular class of cholesterol-lowering drugs, PCSK9 inhibitors, that upregulate or activate the LDL receptor.

The researchers suggest future research to investigate inhibiting ZNF529. They also note this gene does not exist in mice, which limits the ability to study this gene in mice, but also suggests that mammals can survive without this gene.

"Understanding genes and genetic variants impacting the risk of CVD in the context of their biological roles will allow better choices for drug targets that will be more effective at preventing and treating disease, with fewer side effects," says co-corresponding author Chen, M.D., Ph.D., a professor of internal medicine, cardiac surgery, physiology, pharmacology and medicinal chemistry.

Paper cited: "Loss-of-function genomic variants highlight potential therapeutic targets for cardiovascular disease." Nature Communications. DOI: 10.1038/s41467-020-20086-3


More Articles About:

Lab Notes Heart Disease Risk Factors Nonalcoholic fatty liver disease (NAFLD) Genetics Metabolism, Endocrinology & Diabetes Drug Discovery Cardiovascular: Preventive Cardiology
Health Lab word mark overlaying blue cells

Health Lab

Explore thousands of health news & research stories by visiting the Health Lab homepage for more.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

MRNA splicing transcription on a blue background
Health Lab

Study reveals why a rare mutation behind Dravet syndrome is so deadly

Rare mutation behind Dravet syndrome found to be deadly.
Child in blue shirt smiles on the green grass of a football field
Health Lab

FDA approved drug slows type 1 diabetes progression in 5-year-old patient

After a family history of type 1 diabetes led to early screening through TrialNet, 5-year-old Trevor became Michigan's youngest patient to receive delay-inducing drug TZIELD.
Blue round cells in three pictures showing how they change under stress.
Health Lab

Timing is of the essence for RNA during stress

Key determiners of which RNA can be read to make proteins is time. Previous thinking was that a cell under threat would quickly make these RNAs in the nucleus and immediately push them into the cytoplasm.
Family of four poses with plain gray background behind them.
Health Lab

Type 1 diabetes does not mean sitting out for 10 year old

After an influenza infection, 8-year-old was diagnosed with type 1 diabetes at C.S. Mott Children’s Hospital. Read his journey from diagnosis to thriving with T1D.
Gene editing, conceptual illustration. DNA (deoxyribonucleic acid) double helix under a magnifying glass
Health Lab

Gene editing is coming for common diseases. Are we ready?

Gene therapies may offer one-time treatment for disease, but experts say safety, reversibility, cost and long-term monitoring must guide use.
Health Lab

Liver cancer can be preventable. Do you know the treatable risk factors?

Learn about the risks of chronic liver disease, the treatable liver disease factors and how rates of liver cancer have increased.